# End-to-End Closed-Loop Drug Discovery Pipeline Blueprint

## 1. Objective

Design a drug discovery system that integrates biology, chemistry, automation, and ML into a single decision loop. The workflow must support the full progression from target screening through candidate generation, experimental validation, ADMET and toxicity evaluation, synthesis design, and iterative optimization.

The system should not be a linear pipeline. It must be structured as a loop with decision gates and feedback to earlier stages whenever a molecule fails or shows suboptimal behavior.

## 2. Core design principle

A molecule is not a good candidate if it only performs well in one model. A molecule becomes valuable only when it:

- hits the biological target,
- retains activity under orthogonal assays,
- has acceptable selectivity and safety profile,
- survives ADMET and toxicity filters,
- is synthetically accessible,
- is reproducible in physical testing,
- and remains relevant under continuous optimization.

Thus, the system should optimize not for a single scoring metric, but for a portfolio of constraints and objectives.

## 3. Stage breakdown

### Stage 0: Target selection and disease hypothesis

Purpose:
- identify disease-relevant target space
- prioritize targets by tractability, novelty, validation level, and therapeutic relevance

Inputs:
- disease biology data
- omics and pathway analysis
- known target knowledge
- literature and evidence review

Outputs:
- ranked target list
- enabled target modalities (enzymes, GPCRs, protein–protein interactions, etc.)
- decision to move into design or to re-scope target biology

Decision gate:
- if target is weakly tractable or biologically insufficient, return to target analysis and priorization

### Stage 1: AI candidate generation

Purpose:
- generate chemically diverse candidate molecules near the target space
- propose molecules that satisfy key physicochemical and risk constraints

Inputs:
- target structure or biological profile
- known active compounds
- scaffold and chemistry constraints
- preferred chemical space

Methods:
- generative chemistry
- molecular graph generation
- transformer-based molecule generation
- reinforcement or Bayesian optimization loop with biological objectives

Outputs:
- candidate pool with predicted properties
- initial scoring against potency, selectivity, ADMET, and synthesis risk

Decision gate:
- candidates that fail basic property filters are removed or rerouted to a design repair loop

### Stage 2: Property and feasibility scoring

Purpose:
- reduce the search space before sending compounds to wet-lab validation

Metrics:
- synthetic accessibility
- physicochemical constraints
- novelty and diversity
- predicted potency or binding score
- predicted ADMET risk
- likely assay tractability

Outputs:
- ranked shortlist for assay testing
- compounds with explicit rationale for selection

Decision gate:
- a compound with good predicted score but poor realism or synthetic feasibility is repaired or rejected

### Stage 3: CRO protein expression and target validation

Purpose:
- validate that the biological target can be expressed and tested in a reproducible system
- establish assay-ready protein for downstream measurement

Key activities:
- recombinant protein expression
- purification and QC
- relevant construct selection
- assay compatibility evaluation

Outputs:
- assay-ready target proteins
- validated construct quality criteria
- source of variance for subsequent assay design

Decision gate:
- if protein quality is poor or unstable, revise target construct or assay design before moving further

### Stage 4: SPR / binding validation

Purpose:
- measure direct affinity or binding event between protein and candidate
- verify the interaction is real, measurable, and reproducible

Outputs:
- KD, binding mode, potential selectivity indicators
- confidence about true target engagement

Decision gate:
- compounds that show weak or inconsistent SPR response are removed or redesigned

### Stage 5: Enzyme activity and biochemical potency testing

Purpose:
- confirm functional modulation in a biochemical assay
- differentiate true mechanistic inhibition from non-specific binders

Key reads:
- IC50 / EC50
- dose-response shape
- signal-to-background quality
- assay window and reproducibility

Outputs:
- active molecules with measurable potency
- compounds with clear mechanistic promise

Decision gate:
- if potency is weak or assay is noisy, send compounds back to iterative design and assay optimization

### Stage 6: Retention-of-activity and selectivity screening

Purpose:
- confirm that the molecule remains active under relevant conditions and remains selective enough to be useful

This specifically addresses the requirement to test while maintaining or retaining activity, not just initial potency.

Subtests:
- selectivity panel against related targets or family members
- retention of activity under alternative assay conditions
- counter-screening against non-target pathways
- structure-related liability checks

Outputs:
- lead-like shortlist with selectivity profile
- compounds with stronger evidence for mechanism-specific action

Decision gate:
- if activity is retained only in one assay but not under orthogonal or selectivity conditions, the molecule is routed to recapture or redesign

### Stage 7: Toxicity and ADMET profiling

Purpose:
- validate whether hits are safe and usable as drug candidates

Key areas:
- CYP inhibition and metabolism
- permeability and solubility
- plasma protein binding
- hERG liability
- mitochondrial toxicity
- off-target toxicity and organ liability
- genotoxicity and cell viability risk

Outputs:
- risk-ranked candidate set
- ADMET trade-off report

Decision gate:
- if a compound is potent but unsafe or poorly drug-like, it is deprioritized and redesign is triggered

### Stage 8: Automation and assay orchestration

Purpose:
- improve throughput and reduce human bias or delay

Possible components:
- liquid-handling robots
- plate mapping and scheduling
- queue management
- instrumentation integration
- automated result ingestion

Outputs:
- standardized batch execution plan
- reproducibility of assay operation
- faster iterative loop iterations

Decision gate:
- if assay execution quality is poor, the system rebalances QC, batching, and data integration before model retraining

### Stage 9: Synthesis design and route planning

Purpose:
- convert a promising molecule into a feasible experimental synthesis route

Key functions:
- retrosynthesis planning
- route optimization for yield and robustness
- prediction of cost and scale-up feasibility
- medicinal chemistry analog design around synthetic bottlenecks

Outputs:
- preferred synthetic route
- analog series for follow-up design
- priority list for synthesis execution

Decision gate:
- if route feasibility is poor, the molecule is redesigned or replaced by a more synthetically tractable analog

### Stage 10: Synthesis and physical testing

Purpose:
- produce the selected compounds and test them in the relevant assay format

This is the physical validation step where the design loop meets actual chemistry.

Outputs:
- synthesized compounds
- measured physical test results
- updated actual potency and selectivity data

Decision gate:
- if a synthesis fails or measured activity does not match expectation, the system routes back to route redesign, assay redesign, or model retraining

## 4. Feedback and optimization loop

The closed-loop architecture should continuously iterate in this structure:

```text
Target priortization
   ↓
Design candidates
   ↓
Score and filter
   ↓
Protein expression / assay setup
   ↓
SPR / enzyme / selectivity / ADMET
   ↓
Automation and synthesis planning
   ↓
Experiment execution
   ↓
Measured outcomes
   ↓
Retrain + re-rank + regenerate
```

This loop distinguishes a real closed-loop platform from a static AI tool.

## 5. Critical decision criteria at each gate

At each stage, the system must answer three questions:

1. Did the molecule meet minimum performance thresholds?
2. Is the result reproducible and assay-valid?
3. Does the molecule remain promising after considering the broader profile, including ADMET, selectivity, and synthesis feasibility?

If any answer is negative, the system should route back to the most upstream stage that can actually fix the problem.

## 6. Typical failure-to-feedback mapping

- weak binding in SPR → redesign candidate / change scaffold / adjust target hypothesis
- poor enzyme potency → re-tune assay or revisit design space
- retained potency but poor selectivity → redesign around selectivity filter
- poor ADMET → redesign with better physicochemical properties
- poor synthetic access → reformulate route or shift to simpler analogs
- assay noise or robotic failure → fix automation and data QC before retraining

## 7. Product-level implication

A differentiated system is not built around one model or one assay. It is built around a decision engine that turns each wet-lab result into a better next experiment.

The core product value is therefore:

- increased learning efficiency
- lower cost per valid lead
- faster iteration from hypothesis to assay-ready candidates
- better alignment between chemistry, biology, and synthesis

## 8. Short recommendation

If the goal is to build a practical working platform, the best strategy is to start with a reduced but closed loop:

- AI candidate generation
- target assay readiness
- SPR or functional assay
- selectivity and retained activity check
- ADMET rules
- synthesis route planning
- experimental feedback loop

This is the minimal credible loop for meaningful early-stage drug discovery.
